All news

Werner Bauer says good scientific data is 'essential' for communication ... and to substantiate health claims.

Nestlé Clinical Development Unit inauguration

Nestlé centralises clinical research in new centre

By Nathan Gray in Lausanne, Switzerland

Nestlé will centralise the development and management of all of its clinical trials, after the inauguration of its new clinical development unit and metabolic research centre in Lausanne, Switzerland.

Coke backs SATIN satiety project to battle obesity

Dispatches from Vitafoods Europe 2012

Coca-Cola bites into EU-backed obesity project

By Shane Starling from Geneva

What is the world's biggest carbonated beverage company doing in a European Union satiety research project? Why, collaborating to battle obesity of course…

Ganeden takes BC30 probiotic into instant coffee

Ganeden takes BC30 probiotic into instant coffee

By Stephen Daniells

Ganeden Biotech has announced that its BC30 probiotic ingredient will soon be available in instant coffee, as the company builds on success in teas and other beverage formats.

Vitamin D: High levels of vitamin D may have risks too - says study

Vitamin D: Is there such a thing as too much?

By Nathan GRAY

Very high levels of vitamin D could be associated with similar risks as very low levels, according to new research that questions the notion that ‘you can never get too much vitamin D’.

Friends of the Sea backs old and new krill players

Friends of the Sea backs old and new krill players

By Shane Starling

Sustainable seafood NGO Friends of the Sea (FOS) has backed the oldest and biggest krill oil supplier, Canadian krill player Neptune Technologies and Bioressources, along with the newest player in the omega-3 sub-sector, Norwegian firm, Rimfrost.

EndoSeaRch: A new way to modify gut health?

DISPATCHES FROM VITAFOODS EUROPE 2012

EndoSeaRch: A new way to modify gut health?

By Nathan GRAY

A new approach to modifying gut bacteria via orally delivered minerals has been gaining a lot of interest from probiotics players, says Aquapharm.

FDA should reconsider capital costs of AERs: CRN

FDA should reconsider capital costs of AERs: CRN

By Stephen Daniells

The Food & Drug Administration’s (FDA) position that dietary supplement adverse event reporting incurs no  capital costs or operating and maintenance costs is wrong and should be reconsidered, says the Council for Responsible Nutrition (CRN).

Follow us

Products

View more

Webinars